NCT07112209View on ClinicalTrials.gov

Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer

NAEnrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

June 10, 2027

Study Completion Date

November 6, 2027

Conditions

Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer

Interventions

COMBINATION_PRODUCT

Rezvilutamide combined with docetaxel

"Intervention Description:~Drug:Rivarestatine Description: 240mg, po, qd Drug:Docetaxel Description:75mg/m2，ivgtt q3w Drug:Prednisone Description:5mg,po,bid"

Trial Locations (1)

Unknown

Southern Medical University, Guangzhou

All Listed Sponsors

lead

Zhujiang Hospital

OTHER